Trial reportJournal of cosmetic dermatology2025
Recombinant Pure PDGF Improves Aesthetic Results and Patient Satisfaction Following RF Microneedling: A Prospective, Randomized, Controlled Clinical Trial.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recombinant Pure PDGF Improves Aesthetic Results and Patient Satisfaction Following RF Microneedling: A Prospective, Randomized, Controlled Clinical Trial.Journal of cosmetic dermatology · 2025Trial
- Setting the Standard for Peer-Reviewed Published Studies on Regenerative Products in Aesthetic Medicine and Post-Procedure Wound Care.Journal of cosmetic dermatology · 2026Article
- PDGF In Aesthetics: Hype Outpacing the Evidence?Journal of cosmetic dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet-Derived Growth Factor BB (PDGF) is a potent stimulator of tissue regeneration. It has received FDA approvals in four medical therapeutic indications for tissue regeneration. Recently, the use of pure PDGF has also been introduced for the promotion of skin rejuvenation and regeneration in aesthetic indications.
aimsEvaluate the efficacy and safety of the topical application of pure PDGF compared to standard of care following radiofrequency (RF) microneedling.
methodsIn this evaluator-blinded, prospective, randomized, controlled clinical trial, subjects between 30 and 60 years of age received a single treatment of RF microneedling, followed by application of either standard of care (Aquaphor) or pure PDGF. Participants were evaluated at 7 and 30 days post-procedure by a board-certified dermatologist (MG) to determine the Clinical Global Aesthetic Improvement Score (CGAIS), and by Canfield Image Analysis (IA) software to assess seven aesthetic parameters. Patient-reported outcome measures (PROMs) were also obtained at 7 and 30 days following treatment.
resultsPure PDGF treatment resulted in greater improvement in the CGAIS as determined at 7 and 30 days compared to the standard of care group. Additionally, PDGF treatment outperformed the standard of care group in 6 of 7 outcomes in the objective image analysis. PROMs indicated that participants treated with pure PDGF had an overall better experience than participants receiving standard of care. No serious adverse effects were reported.
conclusionsThis prospective, randomized, controlled clinical trial shows the application of pure PDGF possesses an excellent safety profile and improves facial skin quality 30 days post RF microneedling more effectively than the current standard of care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.